Obesity Medicine

ObesityWeek 2021. Weight loss with semaglutide was more than 2 times greater than with liraglutide in the 68-week placebo-controlled trial of the 2 GLP-1 RAs.

ObesityWeek 2021: Regular engagement in online behavioral obesity treatment program within primary care network produced clinically significant weight loss in new study.

A clinical psychologist from the Mayo Clinic Bariatric Center in Jacksonville, FL, explains and corrects key misperceptions that inhibit open discussion of the therapy.

ObesityWeek 2021: New study highlights protective effects of medical weight management during COVID-19 pandemic.

ObesityWeek 2021. Liraglutide helped patients who regained weight after successful gastric bypass surgery re-achieve their lowest weight with an acceptable safety profile.

ObesityWeek 2021: Weight loss support delivered via pandemic-driven telehealth resulted in clinically significant weight loss, report 2 different research teams.

When addressing mental health with patients with obesity, a thoughtful approach that balances psychological health and weight loss is critical, explains Dr Ethan Lazarus.

EASD 2021: Patients with metabolically healthy obesity are nearly 33% more likely to develop heart failure and atrial fibrillation than healthy persons of normal weight, suggests new analysis.

IDWeek 2021: Obesity prevention and vaccination efforts may help prevent COVID-19-related morbidity in pediatric COVID-19 patients with obesity, noted authors of a new study.

EASD 2021: For persons who have had obesity, returning to a healthy weight may reduce risk for hypertension and dyslipidemia, and modestly for diabetes.

More than half of adults in every US state had either overweight or obesity in 2020. This at-a-glance slide show reports more findings from an annual compilation of public data.

A new AHA scientific statement suggests metabolic surgery and weight-loss medications may reduce the long-term effects of obesity-related hypertension.

Social determinants of health vary between patients living in different environments, so what are the key factors to consider when creating a treatment plan?

The risk of transition from overweight to obesity and to more severe obesity is highest among those aged 18- to 24-years-old, according to analysis of data from more than 2 million EHRs.

Why wouldn't a person with severe obesity want to talk about bariatric surgery? Why wouldn't the patient's physician want to do it? The reasons for hesitation are many.

Citing data that show the incidence of type 2 diabetes increases at age 35 years, the Task Force now recommends the younger age to initiate screening vs the current age of 40 years.

Motivational interviewing can significantly help improve the physician-patient relationship. Here, find out 4 key steps to implementing this method in your practice.

Patients with overweight and obesity rarely received guidance on weight management after hospitalization for a coronary event, authors report.

Adding antiobesity medication to a workplace weight-management program among adults with obesity was shown to significantly aid in weight loss in a real-world clinical trial.

Five years after bariatric surgery for uncontrolled T2D patients reported improvements in physical health and QoL but measures of psychosocial wellbeing remained flat.

From obesity to pneumococcal disease, we have picked the top 6 FDA-approved drugs every primary care physician should know about from the second quarter.

Diabetes investigator John Buse, MD, PhD, says laser focus on reducing T2D risk factors is equally as important as using the next right drug against the disease.

Dr Buse’s in-depth review of the GRADE study is followed by a discussion of the keen need for more comparative research and the many new questions the results have raised about optimal T2D therapy.

The much anticipated results from the SURPASS 2 clinical trial demonstrated reductions in A1c and body weight with tirzepatide that were significant and superior to those with semaglutide.

STEP program investigator Robert F. Kushner, MD, reviews the "unprecedented" clinical trial results for semaglutide 2.4 mg and speaks specifically to primary care clinicians treating obesity.

Review of more than 300 clinical trials with products purported to facilitate weight loss found wide variability in risk of bias and data sufficiency suggesting caution among patients and physicians.

It is critical for physicians to urge patients with obesity to get vaccinated against COVID-19 as they are one of the highest risk patient populations.

Adults in their 30s and 40s who had high BMI in adolescence were at highest risk for type 2 diabetes and early MI, regardless of adult BMI, after 24 years of follow-up, a new study finds.

A new study found that patients with severe obesity who had even one discussion about bariatric surgery with a clinician were more likely to lose weight but that the discussions are infrequent.

A new study challenges traditional criteria for patient selection for metabolic surgery, demonstrating significant weight loss and disease remission for those with BMI of 30-35.